PhD Position: RNA Interference-Based Lipid Nanoparticles for Solid Tumour Treatment

This PhD project focuses on the development of RNA interference (RNAi)-based lipid nanoparticles (LNPs) as advanced therapeutic vehicles for the treatment of solid tumours. The research will center on the chemical design and optimization of lipid components to achieve efficient RNA encapsulation, stability, and targeted delivery to cancer cells. Special attention will be given to tailoring lipid composition and integrating targeting strategies that promote selective uptake by tumour cells while minimizing off-target effects. The project will involve evaluating the formulations for their ability to penetrate tumour tissue and induce gene silencing in cancer cell models, followed by in vivo studies to assess biodistribution, tumour accumulation, and therapeutic efficacy. The ultimate goal is to establish a robust nanoparticle platform that combines efficient RNA encapsulation, tumour-targeted delivery, and significant therapeutic activity, paving the way for clinical translation of RNAi-based nanomedicines in oncology. The host institution is the Technion Research and Development Foundation in Haifa, Israel, with research conducted in the Louis Family Laboratory for Targeted Drug Delivery and Personalized Medicine Technologies, led by Prof. Avi Schroeder. The laboratory specializes in innovative medical technologies, particularly targeted drug delivery systems for cancer and neurodegenerative diseases, and offers a multinational, multidisciplinary research environment. The project includes strong collaborations and secondments with Prof. Rory Johnson at University College Dublin, Ireland, and Roy Nevo at Mana Bio Ltd., Israel, requiring a willingness to travel and spend time abroad. Applicants must have a Master’s degree in Organic Chemistry, Chemical Engineering, Biotechnology, Biochemistry, or related fields, and must not already possess a doctoral degree. Research experience in organic chemistry and biochemical techniques is required, with additional experience in chemical synthesis and nanoparticle formulation considered advantageous. Proficiency in English is mandatory, with proof required unless exempted. The position is funded through a doctoral fellowship, including stipend and support for travel and secondments. The application deadline is January 31, 2026. For more information and to apply, visit the INT2ACT recruitment web page.